Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn’s Disease: Efficacy in a Single-Centre Cohort

Alicia López-García,Montserrat Rovira,Aranzazu Jauregui-Amezaga,Pedro Marín,Rebeca Barastegui,Azucena Salas,Vicent Ribas,Faust Feu,J Ignasi Elizalde,Francesc Fernández-Avilés,Carmen Martínez,Gonzalo Gutiérrez,Laura Rosiñol,Enric Carreras,Alvaro Urbano,Miguel Lozano,Joan Cid,María Suárez-Lledó,Maria Carme Masamunt,Dolors Comas,Angel Giner,Marta Gallego,Ignacio Alfaro,Ingrid Ordás,Julian Panés,Elena Ricart
DOI: https://doi.org/10.1093/ecco-jcc/jjx054
2017-04-13
Journal of Crohn's and Colitis
Abstract:BACKGROUND: Haematopoietic stem cell transplantation [HSCT] is considered a therapeutic option for patients with severe Crohn's disease [CD] unresponsive to currently available therapies.METHODS: Autologous HSCT was considered for CD patients with active disease, unresponsive or intolerant to approved medications and unsuitable for surgery. After HSCT, patients were closely followed up every 6 weeks during the first 2 years and every 6 months thereafter up to 5 years. Colonoscopy and/or magnetic resonance imaging were performed at Months 6, 12, 24, and 48 after HSCT.RESULTS: From December 1, 2007 to December 31, 2015, 37 CD patients were assessed for HSCT. Of these, 35 patients [13 within the ASTIC trial] underwent mobilisation. Six patients did not complete the transplant for various reasons and 29 patients were finally transplanted. Patients were followed up during a median of 12 months [6-60]. At 6 months, 70% of patients achieved drug-free clinical remission (Crohn's Disease Index of Severity [CDAI] < 150). The proportion of patients in drug-free remission (CDAI < 150, Simple Endoscopic activity Score [SES]-CD < 7] was 61% at 1 year, 52% at 2 years, 47% at 3 years, 39% at 4 years, and 15% at 5 years. Patients who relapsed were re-treated and 80% regained clinical remission. Six out of the 29 [21%] required surgery. One patient died due to systemic cytomegalovirus infection 2 months after transplant.CONCLUSIONS: HSCT is a salvage therapy for patients with extensive and refractory CD. Although relapse occurs in a majority of patients within 5 years after transplant, drug responsiveness is regained and clinical remission achieved in 80% of cases.
What problem does this paper attempt to address?